Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Shaad Essa Abdullah"'
Autor:
Yashaswi Shrestha, Ronald Herbst, Rajiv Raja, Maria Libera Ascierto, Michael Oberst, Philip Martin, Melissa de los Reyes, Nabendu Pore, Raymond Rothstein, John Meekin, Ashok K. Gupta, Melanie M. Frigault, Stephen Blackmore, Ina Bisha, Nathan Standifer, Shaad Essa Abdullah, Theresa Proia, Matthew Griffin, Phillip A. Dennis, Rebecca A. Halpin, Song Wu, Ricardo J Miragaia, Kathy Mulgrew, J. Carl Barrett, Maria Jure-Kunkel
Publikováno v:
Cancer Discovery. 11:2828-2845
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associate
Autor:
Alexandra Drakaki, Michael S. Gordon, Shaad Essa Abdullah, Wenmei Huang, Michael Ong, Jingsong Zhang, Natasha Angra, Pralay Mukhopadhyay, Xiang Guo, Arnold Degboe, Srikala S. Sridhar, Ashok K. Gupta, Alexander I. Spira, Hendrick Tobias Arkenau, Terence W. Friedlander, Peter H. O'Donnell, Lorin Roskos
Publikováno v:
Cancer. 126:432-443
BACKGROUND: Durvalumab has shown meaningful clinical activity in patients with metastatic urothelial carcinoma (mUC) in Study 1108 (NCT01693562). An important focus in treatment is health‐related quality of life (HRQOL). Here, patient‐reported ou
Autor:
Ryan J. Sullivan, Mohammed M. Milhem, Lev V. Demidov, Karl D. Lewis, Max Schlaak, Sophie Piperno-Neumann, Shaad Essa Abdullah, Claire Watkins, Howard Goodall, John M. Kirkwood
Publikováno v:
Journal of Clinical Oncology. 40:9585-9585
9585 Background: Tebentafusp (tebe) is the first T cell receptor therapeutic to demonstrate overall survival (OS) benefit in a randomized Phase 3 study vs investigator’s choice (IC) [ NCT03070392 ]. OS benefit was also observed in patients (pts) wi
Autor:
Mark R. Middleton, Omid Hamid, Alexander Noor Shoushtari, Friedegund Elke Meier, Todd Michael Bauer, April K.S. Salama, John M. Kirkwood, Paolo Antonio Ascierto, Paul Lorigan, Cornelia Mauch, Marlana M. Orloff, T.R. Jeffry Evans, Shaad Essa Abdullah, Yuan Yuan, James Mitchell, Jessica Cecile Hassel
Publikováno v:
Journal of Clinical Oncology. 40:104-104
104 Background: Tebe is a T-cell receptor bispecific (gp100 x CD3) against gp100 peptide-HLA-A2 complexes that are overexpressed in uveal (UM)/cutaneous melanoma (CM). Tebe is the only therapy to show an OS benefit (HR 0.51) in a phase (Ph) 3 trial i
Autor:
Alexandra Ikeguchi, Joseph J. Sacco, Jason J. Luke, T.R. Jeffry Evans, Brendan D. Curti, Kevin B. Kim, Shaad Essa Abdullah, Claire Watkins, Ozgur Karakuzu, Paul D. Nathan
Publikováno v:
Journal of Clinical Oncology. 40:9584-9584
9584 Background: All immune therapies that rapidly activate T cells, including T cell engagers, can induce cytokine release syndrome (CRS). Tebentafusp (tebe), a T cell receptor bispecific (gp100 x CD3) can also induce skin adverse events (AEs), due
Autor:
Shaad Essa Abdullah, Bartosz Chmielowski, Igor Puzanov, P. Mendez, S. Lockwood, P.A. Ascierto, Friedegund Meier, Ellen Kapiteijn
Publikováno v:
Annals of Oncology. 32:S856-S857
Autor:
Shaad Essa Abdullah, Joseph J. Sacco, Laura C. Collins, S. Stanhope, L. de la Cruz Merino, Koustubh Ranade, Z. Eroglu, A. Greenshields-Watson
Publikováno v:
Annals of Oncology. 32:S1214-S1215
Autor:
Andrea Necchi, Daniel Hennessy, Juliane Manitz, Toni K. Choueiri, Noah M. Hahn, Shaad Essa Abdullah, Chen Gao, Constanze Kaiser, Ashok K. Gupta, Sandy Srinivas, Andrea B. Apolo, Jonathan E. Rosenberg, Darren Tayama, Doris Makari, Gregory R. Pond, Guru Sonpavde, Dean F. Bajorin, Matthew D. Galsky, Thomas Powles, Petros Grivas, Robert Dreicer, Guenter Niegisch
Publikováno v:
J Urol
PURPOSE: A prognostic model for overall survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-1/PD-L1 inhibitors is necessary as existing models were constructed in the chemotherapy setting. MATERIALS AND METHODS: Patie
Autor:
Song Wu, Matthew D. Hellmann, Han Si, Jean-Charles Soria, Maria Libera Ascierto, Rajiv Raja, Caroline Germa, Nathan Standifer, Chris Morehouse, Carl Barrett, Shaad Essa Abdullah, Marlon Rebelatto
Publikováno v:
Regular and young investigator award abstracts.
Background Despite the encouraging successes of immune checkpoint inhibitors, many patients do not benefit and are either refractory or relapse. The mechanisms of refractory or relapsed disease following PD-(L)1 blockade are largely unknown. To ident
Autor:
Richard D. Carvajal, Douglas B. Johnson, Alexander N. Shoushtari, Jason J. Luke, Joseph J. Sacco, Omid Hamid, Josep M. Piulats, Shaad Essa Abdullah, Enrique Espinosa, Michelle L. McCully, Marcus W. Butler, Leonel Hernandez-Aya, Jessica C. Hassel, Christopher J. Holland, Serge Leyvraz, Alexandra Ikeguchi, Paul C. Nathan, Matthew J. Rioth, Takami Sato
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundTebentafusp, a bispecific fusion protein consisting of an affinity-enhanced T cell receptor fused to an anti-CD3 effector that can redirect T cells to target gp100+ cells, has shown an overall survival benefit for patients with untreated me